Sarepta Therapeutics
SRPT
13.33
-0.84
-5.93%
Sarepta Therapeutics
US · SRPT
#2853 by market cap
Listed 1970
13.33
-0.84
-5.93%
Periodic snapshot; not a real-time feed.
· 2026-11-20 19:54
Recent news
-
Rating change
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Cuts Target Price to $18Market Newswire · 2026/10/9
-
Rating change
Analysts' Opinions Are Mixed on These Healthcare Stocks: Vericel (VCEL), Sarepta Therapeutics (SRPT) and Neumora Therapeutics, Inc. (NMRA)TipRanks · 2026/7/28
-
Barclays Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/11/9
-
Rating change
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Raises Target Price to $23Market Newswire · 2026/9/2
-
Company notice
Tradr 2X Long SRPT Daily ETF: Tradr 2X Long SRPT Daily ETF - Liquidation/Cash Settlement/Acceleration of Expirations Option Symbol: SRPUOCC · 2026/6/24
-
Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13Market Newswire · 2026/11/9
-
Rating change
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Announces Target Price $20Market Newswire · 2026/9/30
-
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/11/13
-
Rating change
H.C. Wainwright Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $5Market Newswire · 2026/10/30
-
Company notice
Tradr 2X Long SRPT Daily ETF | 497: Periodic update to fund prospectusSEC · 2026/5/21
-
Rating change
Wedbush Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $35Market Newswire · 2026/10/26
-
Rating change
Needham Maintains Sarepta Therapeutics(SRPT.US) With Sell RatingMarket Newswire · 2026/9/28
-
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38Market Newswire · 2026/11/7
-
Rating change
J.P. Morgan Remains a Hold on Sarepta Therapeutics (SRPT)TipRanks · 2026/9/2
-
Rating change
Evercore Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $19Market Newswire · 2026/8/10
-
Rating change
William Blair Initiates Sarepta Therapeutics(SRPT.US) With Hold RatingMarket Newswire · 2026/9/29
-
Company notice
Tradr 2X Long SRPT Daily ETF: Tradr 2X Long SRPT Daily ETF - Anticipated Liquidation/Anticipated Cash Settlement Option Symbol: SRPUOCC · 2026/6/4
-
Deutsche Bank Upgrades Sarepta Therapeutics(SRPT.US) to Hold Rating, Raises Target Price to $18Market Newswire · 2026/11/10
-
Rating change
J.P. Morgan Maintains Sarepta Therapeutics(SRPT.US) With Hold RatingMarket Newswire · 2026/9/15
-
Rating change
BofA Securities Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $18Market Newswire · 2026/11/2
-
Rating change
A Quick Look at Today's Ratings for Sarepta Therapeutics(SRPT.US), With a Forecast Between $5 to $38Market Newswire · 2026/8/7
-
Rating change
Mizuho Securities Maintains Sarepta Therapeutics(SRPT.US) With Buy Rating, Maintains Target Price $31Market Newswire · 2026/7/10
-
Rating change
Morgan Stanley Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $25Market Newswire · 2026/7/27
-
Rating change
Citi Maintains Sarepta Therapeutics(SRPT.US) With Sell Rating, Maintains Target Price $13Market Newswire · 2026/9/28
-
Piper Sandler Maintains Sarepta Therapeutics(SRPT.US) With Hold Rating, Maintains Target Price $20Market Newswire · 2026/10/19
Headlines are aggregated automatically and are not independently verified or edited by our team.
Quote time 2026-11-20 19:54:28 · For reference only, not investment advice and not tailored to your situation.
Sarepta Therapeutics discussion 0 comments